Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Dec 03, 2023 8:39am
110 Views
Post# 35765692

RE:RE:RE:RE:RE:RE:RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO

RE:RE:RE:RE:RE:RE:RE:RE:ONCY Presented Positive GOBLET Pancreatic Cancer Data @ ESMO
Jensen Huang, the Nvidia chief executive, reflects on the company’s origins and what drives him
Huang told the story of the first A.I. supercomputer he built, which he delivered to Musk for OpenAI. Building it took five years starting in 2012. The economist Glenn Hubbard said that he found the story particularly useful. “Too often, for companies that have exploded in value, like Nvidia, you think of it as kind of a flash in the pan, and he’s saying, ‘No, no, no, no, no, no, I was at this for 30 years,’” Hubbard said. “The fact that it takes a long time, but eventually things take off, I thought was a really excellent message.”

oncy has only been at it for 25 years but seems the time is right for our "flash in the pan" moment.
<< Previous
Bullboard Posts
Next >>